Skip to main content
Premium Trial:

Request an Annual Quote

Hybridon Granted Patent on Circular Oligonucleotides For Antisense

NEW YORK, May 20-The antisense chemistry company Hybridon said today that it has been issued a U.S. patent for its class of novel circular oligonucleotides.

 

These oligonucleotides are designed so that a functional domain and a protective domain are linked together in a circular structure. As the functional domain binds to its target mRNA, the circular structure opens to inhibit target protein expression.

 

According to Hybridon, this structure improves stability and decreases non-specific interactions.

 

This second-generation technology is being developed for a range of antisense applications, including target validation, antinses drugs and diagnostic probes.

 

Hybridon's patent was issued by the U.S. Patent and Trade Office on May 7.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.